**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | ESMO VJC NSCLC | **Project Code** | **PB4VVJ086** |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Sanneke Koekkoek |
| **Compliance** | Briana Devaser | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

**October 30, 2014**

**Project Type**

Virtual Journal Club (Video)

Downloadable Slides

Podcast

Downloadable Manuscript

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
Content Available by:

**CME?**

Yes

No

**CME Posttest Link:**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**2014 ESMO VJC NSCLC**

Please add your content to the form below and remove any content that is irrelevant to your activity. If something gets updated, please update this document.

**\*\*\*DO NOT LIST “SEE ATTACHED DOCUMENT”.**

**This is the only copy document that should be sent to Design.\*\*\***

**Items highlighted in YELLOW should be completed by the Clinical Team**

**Items highlighted in TEAL should be determined at the Kickoff Meeting**

**In terms of LEAN, virtual products differ in that all sections should be complete prior to sending this form to Web (there is no minimum number of sections).**

1. **[Title---always italicized, no bold, no quotes]**

*The Changing Landscape of Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer Treatment*

1. **[Activity Date]**

**Release Date:**

October 30, 2014

**Expiration Date:**

October 30, 2015

1. **[Activity Overview]**

This CME-certified independent medical education activity features an expert interview with **Francesco Grossi, MD,**and **Martin Reck, MD, PhD,** as they discuss the recently publishedfinal results of the international randomized phase II study NAVotrial 01.

Drs Grossi and Reck discuss the following recently published manuscript:

Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)

Bennouna J, et al. *Clin Lung Cancer.* 2014;15(4):258-265.

1. **[Target Audience]**

This activity is intended for medical oncologists, pulmonologist, pathologists, and other healthcare professionals involved in the treatment of patients with nonsquamous non-small cell lung cancer (NSCLC).

1. **[Learning Objectives]**

After successful completion of this educational activity, participants should be able to:

* Describe current chemotherapeutic options for patients with nonsquamous NSCLC
* Evaluate recently published clinical trial data that focuses on comparing different chemotherapeutic regimens in the treatment of nonsquamous NSCLC
* Discuss how these recently published data are likely to influence current and future clinical practice when treating patients with nonsquamous NSCLC

***[NOTE: learning objectives must be specific, measurable, attainable, relevant, time limited]***

1. **[Faculty Listing/Featured Experts/Discussants….Faculty Listing and Featured Experts sections are stacked, Discussants section is in-line]**

**Featured Experts**

Francesco Grossi, MD

National Institute for Cancer Research

Genoa, Italy

Martin Reck, MD, PhD

Hospital Grosshansdorf

Grosshansdorf, Germany

1. **Provider**

This activity is provided by prIME Oncology.

1. **[Continuing Education---choose one]**

**US CME**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

[Insert ACCME logo]

prIME Oncology designates this enduring activity for a maximum of *0.25 AMA PRA Category 1 Credits™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

\*\*All CME/CE verbiage should receive final approval from Regulatory/Compliance Manager

Method of Participation Section is missing

1. **Support Statement [ACCME—consult Cindy for proper verbiage and defer to BD for final approval of complete verbiage]**

This educational activity is supported by a grant from Pierre Fabre Pharmaceuticals.

1. **[Disclosures]**

**CME**

**Disclosure of Relevant Financial Relationships**

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Grossi has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Reck has disclosed that he has received consulting fees from AstraZeneca, Boehringer-Ingleheim, Bristol-Myers Squibb, Hoffmann-La Roche, Lilly, Novartis, and Pfizer. He has also received non-CME fees from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Hoffmann-La Roche, Lilly, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Janice Galleshaw, MD (medical content reviewer/planner) – no relevant financial relationships
* Sanneke Koekkoek, RN (clinical content reviewer/planner) – no relevant financial relationships
* Christi Gray (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1. **[URL and Mobile App Name---give suggestions for URL name] \*\*\*Should be discussed and decided upon at the Kickoff Meeting.**

Insert URL here.

www.primeoncology.org/2014VJCNSCLC\_Madrid

\*\*Note: Do not include the name of the congress or society in the URL.

Page Title

Primary Keyword | Secondary Keyword

Insert Mobile App Name (restricted to 23 characters, including spaces. Conference names and abbreviations [ie, ASCO, ISHL] are appropriate to use. Do not include the location or year in the title. For Web activities, it is not necessary to include the type of activity [ie, CSP, Expert Review] in the title, as this will be indicated below the title. For Webcasts, use the same app title as was used for the live activity): **2014 ESMO VJC NSCLC**

Meta Description   
This discussion is focused on the treatment of patients with nonsquamous NSCLC and final NAVotrial 01 data.

Key Words/Key Phrases

Nonsquamous

NSCLC

NAVoTrial01

Vinorelbine

Oral vinorelbine

Bennouna

ESMO guideline

EGFR

ALK

1. **[Subject Line for Email Blast]**

A. Insert Email Blast Subject Line A copy here.

B. Insert Email Blast Subject Line B copy here.

1. **[Email Blast Copy]**

Either list parts above that are to be included in the email blast or insert new (different) copy that is to be used in the email blast.

Example:

Title

Date/Time

Faculty

Topics

Target Audience

Learning Objectives

Continuing Education Statement

Credit Designation Statement

Disclosures

Providership (with logos)

Support (no logos)

1. **[Other]**

Please add any additional copy needed but not listed above with a description of what it is and where it is needed.